Klinischer Stellenwert der „liquid biopsy“ beim Mammakarzinom

Translated title of the contribution: Clinical significance of liquid biopsy in breast cancer

Maggie Banys-Paluchowski*, Tanja Fehm

*Corresponding author for this work


Background: Detection of tumor cells, tumor DNA and RNA in the blood and other body fluids is referred to as liquid biopsy. It enables the evaluation of the disease without the necessity of an invasive tissue biopsy and makes serial measurements (“real-time biopsy”) possible. Materials and methods: An evaluation of current evidence from clinical trials and conference proceedings was performed. Results: The presence of circulating tumor cells (CTCs) in the blood of breast cancer patients is associated with poor clinical outcome in early and metastatic settings. Patients with PIK3CA mutations in the circulating tumor DNA benefit from targeted therapy with a PI3K inhibitor alpelisib. Conclusion: Liquid biopsy-based strategies may contribute to further personalization of breast cancer therapy.

Translated title of the contributionClinical significance of liquid biopsy in breast cancer
Original languageGerman
Issue number8
Pages (from-to)736-745
Number of pages10
Publication statusPublished - 01.08.2020

Research Areas and Centers

  • Research Area: Luebeck Integrated Oncology Network (LION)
  • Centers: University Cancer Center Schleswig-Holstein (UCCSH)


Dive into the research topics of 'Clinical significance of liquid biopsy in breast cancer'. Together they form a unique fingerprint.

Cite this